Functional changes in murine mammary cancer cells elicited by CoCl2-induced hypoxia

Nitric Oxide - Biology and Chemistry

Volumn 23, Issue 3, 2010, Pages 234-241

  Borenstein, Ximena ^a   Fiszman, Gabriel L ^a   Blidner, Ada ^a   Vanzulli, Silvia I ^b   Jasnis, María A ^a  

^a Instituto de Oncologia Angel H Roffo   (Argentina)

^b ACADEMIA NACIONAL DE MEDICINA   (Argentina)

Author keywords

CoCl2; Macrophages; NO; Tumor hypoxia

Indexed keywords

COBALT CHLORIDE; GELATINASE B; NITRIC OXIDE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CARCINOGENICITY; CELL FUNCTION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; HYPOXIA; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANOXIA; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COBALT; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MACROPHAGES; MICE; MICE, INBRED BALB C; NITRIC OXIDE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 77956010701     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2010.07.003     Document Type: Article

References (55)

1. Zhang H., Semenza G.L. The expanding universe of hypoxia. J. Mol. Med. 2008, 86:739-746.
2. Kronblad A., Jirstrom K., Ryden L., Nordenskjold B., Landberg G. Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int. J. Cancer 2006, 118:2609-2616.
3. Ameri K., Luong R., Zhang H., Powell A.A., Montgomery K.D., Espinosa I., Bouley D.M., Harris A.L., Jeffrey S.S. Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br. J. Cancer 2010, 102:561-569.
4. 2 availability on human cancer. Nat. Rev. Cancer 2008, 8:967-975.
5. Osinsky S., Zavelevich M., Vaupel P. Tumor hypoxia and malignant progression. Exp. Oncol. 2009, 31:80-86.
6. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
7. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., Moons L., Jain R.K., Collen D., Keshert E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394:485-490.
8. Dang C.V., Kim J.W., Gao P., Yustein J. The interplay between MYC and HIF in cancer. Nat. Rev. Cancer 2008, 8:51-56.
9. Izuishi K., Kato K., Ogura T., Kinoshita T., Esumi H. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res. 2000, 60:6201-6207.
10. Zhou J., Dehne N., Brune B. Nitric oxide causes macrophage migration via the HIF-1-stimulated small GTPases Cdc42 and Rac1. Free Radic. Biol. Med. 2009, 47:741-749.
11. Wellman T.L., Jenkins J., Penar P.L., Tranmer B., Zahr R., Lounsbury K.M. Nitric oxide and reactive oxygen species exert opposing effects on the stability of hypoxia-inducible factor-1alpha (HIF-1alpha) in explants of human pial arteries. FASEB J. 2004, 18:379-381.
12. Xu W., Liu L.Z., Loizidou M., Ahmed M., Charles I.G. The role of nitric oxide in cancer. Cell Res. 2002, 12:311-320.
13. Rankin E.B., Giaccia A.J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008, 15:678-685.
14. Murdoch C., Giannoudis A., Lewis C.E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004, 104:2224-2234.
15. Urtreger A., Ladeda V., Puricelli L., Riveli A., Vidal M.C., Lustig E.S., Bal de Kier Joffé E. Modulation of fibronectin expression and proteolytic activity associated with the invasive and metastatic phenotype in two murine mammary cell lines. Int. J. Oncol. 1997, 11:489-496.
16. Vengellur A., LaPres J.J. The role of hypoxia inducible factor 1alpha in cobalt chloride induced cell death in mouse embryonic fibroblasts. Toxicol. Sci. 2004, 82:638-646.
17. Granger D.L., Hibbs J.B., Perfect J.R., Durack D.T. Metabolic fate of l-arginine in relation to microbiostatic capability of murine macrophages. J. Clin. Invest. 1990, 85:264-273.
18. Shin C.Y., Lee W.J., Choi J.W., Choi M.S., Ryu J.R., Oh S.J., Cheong J.H., Choi E.Y., Ko K.H. Down-regulation of matrix metalloproteinase-9 expression by nitric oxide in lipopolysaccharide-stimulated rat primary astrocytes. Nitric Oxide 2007, 16:425-432.
19. Mirkina, Mernenko O.A., Satpaev D.K., Karelin A.A., Blishchenko E. Cytolytic processes induced by TNF in L929 and K562 differ in DNA fragmentation mechanisms. Immunol. Lett. 1996, 52:105-108.
20. Fujiwara S., Nakagawa K., Harada H., Nagato S., Furukawa K., Teraoka M., Seno T., Oka K., Iwata S., Ohnishi T. Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int. J. Oncol. 2007, 30:793-802.
21. Akakura N., Kobayashi M., Horiuchi I., Suzuki A., Wang J., Chen J., Niizeki H., Kawamura K., Hosokawa M., Asaka M. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 2001, 61:6548-6554.
22. Indovina P., Collini M., Chirico G., Santini M.T. Three-dimensional cell organization leads to almost immediate HRE activity as demonstrated by molecular imaging of MG-63 spheroids using two-photon excitation microscopy. FEBS Lett. 2007, 581:719-726.
23. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
24. Beasley N.J., Leek R., Alam M., Turley H., Cox G.J., Gatter K., Millard P., Fuggle S., Harris A.L. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 2002, 62:2493-2497.
25. Volm M., Koomagi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 2000, 20:1527-1533.
26. Jung J.Y., Mo H.C., Yang K.H., Jeong Y.J., Yoo H.G., Choi N.K., Oh W.M., Oh H.K., Kim S.H., Lee J.H., Kim H.J., Kim W.J. Inhibition by epigallocatechin gallate of CoCl2-induced apoptosis in rat PC12 cells. Life Sci. 2007, 80:1355-1363.
27. Yao K., Gietema J.A., Shida S., Selvakumaran M., Fonrose X., Haas N.B., Testa J., O'Dwyer P.J. In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo. Br. J. Cancer 2005, 93:1356-1363.
28. Kimura H., Weisz A., Kurashima Y., Hashimoto K., Ogura T., D'Acquisto F., Addeo R., Makuuchi M., Esumi H. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000, 95:189-197.
29. Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide 2008, 19:205-216.
30. Callapina M., Zhou J., Schnitzer S., Metzen E., Lohr C., Deitmer J.W., Brune B. Nitric oxide reverses desferrioxamine- and hypoxia-evoked HIF-1alpha accumulation-implications for prolyl hydroxylase activity and iron. Exp. Cell Res. 2005, 306:274-284.
31. Kalpana S., Dhananjay S., Anju B., Lilly G., Sai Ram M. Cobalt chloride attenuates hypobaric hypoxia induced vascular leakage in rat brain: molecular mechanisms of action of cobalt chloride. Toxicol. Appl. Pharmacol. 2008, 231:354-363.
32. Eijan A.M., Davel L.E., Rueda H.A., Rozenberg G., De Lustig E.S., Jasnis M.A. Differential nitric oxide release and sensitivity to injury in different murine mammary tumor cell lines. Int. J. Mol. Med. 1998, 2:625-630.
33. Jasnis M.A., Davel L.E., Eijan A.M., Klein D., De Lustig E.S. Nitric oxide is involved in stimulation of tumor growth. Oncol. Rep. 1997, 4:1107-1111.
34. Davel L., D'Agostino A., Espanol A., Jasnis M.A., Lauria de Cidre L., de Lustig E.S., Sales M.E. Nitric oxide synthase-cyclooxygenase interactions are involved in tumor cell angiogenesis and migration. J. Biol. Regul. Homeost. Agents 2002, 16:181-189.
35. Davel L.E., Rimmaudo L., Espanol A., de la Torre E., Jasnis M.A., Ribeiro M.L., Gotoh T., de Lustig E.S., Sales M.E. Different mechanisms lead to the angiogenic process induced by three adenocarcinoma cell lines. Angiogenesis 2004, 7:45-51.
36. Grimm E.A., Ellerhorst J., Tang C.H., Ekmekcioglu S. Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide 2008, 19:133-137.
37. Palmer L.A., Semenza G.L., Stoler M.H., Johns R.A. Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am. J. Physiol. 1998, 274:L212-219.
38. Magenta G., Sales M.E., Davel L., Lustig E.S., Jasnis M.A. Participación de NOS constitutiva e inducible en la viabilidad de células tumorales. Medicina (B Aires) 2002, 62.
39. Wang C., Trudel L.J., Wogan G.N., Deen W.M. Thresholds of nitric oxide-mediated toxicity in human lymphoblastoid cells. Chem. Res. Toxicol. 2003, 16:1004-1013.
40. Pervin S., Singh R., Chaudhuri G., oxide Nitric N omega-hydroxy-l-arginine and breast cancer. Nitric Oxide 2008, 19:103-106.
41. Murdoch C., Muthana M., Lewis C.E. Hypoxia regulates macrophage functions in inflammation. J. Immunol. 2005, 175:6257-6263.
42. Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 2006, 16:3-15.
43. Cowden Dahl K.D., Robertson S.E., Weaver V.M., Simon M.C. Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression. Mol. Biol. Cell 2005, 16:1901-1912.
44. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
45. Brahimi-Horn C., Pouyssegur J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull. Cancer 2006, 93:E73-80.
46. Indovina P., Rainaldi G., Santini M.T. Hypoxia increases adhesion and spreading of MG-63 three-dimensional tumor spheroids. Anticancer Res. 2008, 28:1013-1022.
47. Grimshaw M.J., Balkwill F.R. Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation-a potential mechanism. Eur. J. Immunol. 2001, 31:480-489.
48. Zhang L., Hill R.P. Hypoxia enhances metastatic efficiency in HT1080 fibrosarcoma cells by increasing cell survival in lungs, not cell adhesion and invasion. Cancer Res. 2007, 67:7789-7797.
49. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
50. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 2007, 117:1155-1166.
51. Ladeda V., Adam A.P., Puricelli L., Bal de Kier Joffe E. Apoptotic cell death in mammary adenocarcinoma cells is prevented by soluble factors present in the target organ of metastasis. Breast Cancer Res. Treat. 2001, 69:39-51.
52. Degrossoli A., Giorgio S. Functional alterations in macrophages after hypoxia selection. Exp. Biol. Med. (Maywood) 2007, 232:88-95.
53. Yun J.K., McCormick T.S., Villabona C., Judware R.R., Espinosa M.B., Lapetina E.G. Inflammatory mediators are perpetuated in macrophages resistant to apoptosis induced by hypoxia. Proc. Natl. Acad. Sci. USA 1997, 94:13903-13908.
54. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27:5904-5912.
55. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634.